-- 週一盤後交易中,歐洲天然氣期貨價格小幅走低,此前有報道稱,伊朗提議以美國解除封鎖為條件,重新開放霍爾木茲海峽。 荷蘭TTF天然氣近月合約下跌0.92%,至每兆瓦時44.45歐元(52.14美元);英國NBP基準天然氣合約下跌1.48%,至每熱量單位110.25便士(1.49美元)。 媒體報道稱,伊朗提出,如果華盛頓解除經濟和軍事壓力並同意停止敵對行動,伊朗將解除霍爾木茲海峽過境的限制。據報道,該提案將推遲有關伊朗核計畫的談判。 此前,原定於週末在巴基斯坦舉行的第二輪美伊和平談判未能如期舉行。 霍爾木茲海峽是全球液化天然氣運輸的重要通道,約佔全球液化天然氣運輸量的五分之一,目前已連續九週處於關閉狀態。然而,根據霍爾木茲海峽監測報告,過去24小時內有19艘船舶通過該海峽,顯示船舶通行量有所增加。 卡達的基礎設施受損加劇了供應方面的擔憂。國際能源總署週五警告稱,中斷可能導致一項大型液化天然氣擴建項目至少延長兩年,並可能在2026年至2030年間使市場供應減少1,200億立方公尺。 該機構表示:“雖然其他地區的新液化項目有望隨著時間的推移彌補這些損失,但此次事件的影響將使市場供應緊張的局面持續到2026年和2027年。” 與此同時,歐洲天然氣庫存水準仍面臨壓力。根據歐洲天然氣基礎設施協會(Gas Infrastructure Europe)的數據,庫存佔總容量的31.47%,而去年同期為38.14%。 Timera Energy表示,4月的低庫存水準意味著,即使將庫存目標下調至80%,歐洲也需要達到與去年夏季類似的注入速度。儘管目前緩慢的注入速度有助於穩定全球價格,但該公司警告稱,未來幾個月可能需要持續增產。 蒂梅拉表示,如果中東緊張局勢無法迅速解決,歐洲可能需要積極競購液化天然氣貨物以確保供應,這可能會推高價格,並導致部分貨物從亞洲買家手中轉移。
Related Articles
Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set
Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.
Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.